We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+13.4%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$2.23B
AUM Growth
-$147M
(-6.2%)
Cap. Flow
-$391M
Cap. Flow
% of AUM
-17.54%
Top 10 Holdings %
Top 10 Hldgs %
45.21%
Holding
76
New
10
Increased
18
Reduced
33
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SHPG
Shire pic
SHPG
|
+$34.9M |
| 2 |
FOLD
Amicus Therapeutics
FOLD
|
+$31.3M |
| 3 |
ACHN
Achillion Pharmaceuticals
ACHN
|
+$29M |
| 4 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$22.3M |
| 5 |
Medtronic
MDT
|
+$21.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$64.7M |
| 2 |
Amgen
AMGN
|
+$44.1M |
| 3 |
Viatris
VTRS
|
+$34.4M |
| 4 |
AbbVie
ABBV
|
+$25.7M |
| 5 |
CELG
Celgene Corp
CELG
|
+$24.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Biogen
BIIB
$29.2B
| $149M | 6.69% |
439,428
-74,978
| -15% | -$24.3M |
|
|
2
Amgen
AMGN
$198B
| $142M | 6.39% |
894,473
-282,728
| -24% | -$44.1M |
|
|
CELG
3
DELISTED
Celgene Corp
CELG
| $127M | 5.69% |
1,134,258
-230,514
| -17% | -$24.3M |
|
4
BioMarin Pharmaceuticals
BMRN
$11.3B
| $113M | 5.08% |
1,253,243
-125,757
| -9% | -$10.5M |
|
5
Incyte
INCY
$23.1B
| $97.4M | 4.37% |
1,332,814
-298,998
| -18% | -$19.5M |
|
|
6
Viatris
VTRS
$19.8B
| $85.6M | 3.84% |
1,519,368
-640,483
| -30% | -$34.4M |
|
7
Teva Pharmaceuticals
TEVA
$35.1B
| $79.4M | 3.56% |
1,380,888
-327,303
| -19% | -$18.2M |
|
8
Regeneron Pharmaceuticals
REGN
$68.3B
| $76.2M | 3.42% |
185,685
-42,115
| -18% | -$16.6M |
|
|
ALXN
9
DELISTED
Alexion Pharmaceuticals
ALXN
| $71.4M | 3.2% |
385,624
-101,784
| -21% | -$18.9M |
|
|
AGN
10
DELISTED
Allergan plc
AGN
| $66.1M | 2.97% |
256,850
-91,000
| -26% | -$22.7M |
|
11
Thermo Fisher Scientific
TMO
$196B
| $65.2M | 2.93% |
520,686
-3,914
| -0.7% | -$476K |
|
|
12
Gilead Sciences
GILD
$162B
| $64.5M | 2.89% |
684,307
-625,609
| -48% | -$64.7M |
|
13
PTC Therapeutics
PTCT
$6.5B
| $58.8M | 2.64% |
1,135,130
-187,268
| -14% | -$8.24M |
|
|
NPSP
14
DELISTED
NPS PHARMACEUTICALS INC
NPSP
| $58.1M | 2.6% |
1,623,073
-103,751
| -6% | -$3.1M |
|
|
SHPG
15
DELISTED
Shire pic
SHPG
| $50.2M | 2.25% |
236,124
+164,588
| +230% | +$34.9M |
|
|
KERX
16
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $46.1M | 2.07% |
3,257,358
-357,768
| -10% | -$5.54M |
|
|
MNK
17
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $39.7M | 1.78% |
400,664
-199,800
| -33% | -$18.4M |
|
|
FOLD
18
DELISTED
Amicus Therapeutics
FOLD
| $39.6M | 1.78% |
4,765,498
+4,565,498
| +2,283% | +$31.3M |
|
19
Perrigo
PRGO
$1.45B
| $38.8M | 1.74% |
232,068
-135,500
| -37% | -$21.2M |
|
20
Dr. Reddy's Laboratories
RDY
$9.48B
| $38.5M | 1.73% |
3,814,845
+140,110
| +4% | +$1.47M |
|
21
Pfizer
PFE
$141B
| $37.7M | 1.69% |
1,275,249
+406,807
| +47% | +$11.7M |
|
22
Halozyme
HALO
$9.23B
| $35.9M | 1.61% |
3,724,351
-834,631
| -18% | -$7.42M |
|
|
MDVN
23
DELISTED
MEDIVATION, INC.
MDVN
| $35.5M | 1.59% |
713,612
+39,856
| +6% | +$2.07M |
|
|
SGEN
24
DELISTED
Seagen Inc. Common Stock
SGEN
| $35.5M | 1.59% |
1,104,075
+494,256
| +81% | +$17.2M |
|
|
OMED
25
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $34.8M | 1.56% |
1,598,293
-96,224
| -6% | -$1.97M |
|
Similar funds
RIP
LFWA
CF
WIM
MW
AFC
AAA
TGM
Sectoral Asset Management's Q4 2014 Portfolio in Review
As of Q4 2014, Sectoral Asset Management held 76 positions worth $2.23B, down 6.2% from $2.38B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Sectoral Asset Management withdrew a net $391M in Q4 2014, closing 12 positions and reducing 33 holdings. Its most notable exit was AbbVie, an estimated $25.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 89% a quarter earlier.
Against the trend, Sectoral Asset Management opened a new position in Achillion Pharmaceuticals worth $29.1M.
- Sectoral Asset Management's largest Q4 2014 buy was Achillion Pharmaceuticals: 2,373,810 shares worth $29.1M.
- Sectoral Asset Management added most to Shire pic in Q4 2014, an estimated $34.9M increase.
- Sectoral Asset Management's biggest Q4 2014 reduction was Gilead Sciences, cutting an estimated $64.7M.
- Sectoral Asset Management fully exited AbbVie in Q4 2014, selling an estimated $25.7M.
- Sectoral Asset Management's ten largest holdings make up 45% of its $2.23B portfolio in Q4 2014.
- Sectoral Asset Management opened 10 new positions and closed 12 in Q4 2014.
- Sectoral Asset Management's portfolio value fell 6.2% quarter-over-quarter to $2.23B.
Based on Sectoral Asset Management's 13F filing for Q4 2014, filed 13 Feb 2015.